Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

34
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

1.1K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.

Hepatology (Baltimore, Md.)·2026
Same author

Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.

Journal of hepatology·2025
Same author

Navigating Hepatocellular Carcinoma.

Clinics in liver disease·2024
Same author

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

The New England journal of medicine·2023
Same author

Autoimmune Hepatitis: Epidemiology, Subtypes, and Presentation.

Clinics in liver disease·2023
Same author

Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

Alimentary pharmacology & therapeutics·2023

Related Experiment Video

Updated: Mar 28, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Universal screening for chronic hepatitis C virus.

Mitchell L Shiffman1

  • 1Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA, USA.

Liver International : Official Journal of the International Association for the Study of the Liver
|January 5, 2016
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) screening is recommended for the 1945-1965 birth cohort, but universal screening and treatment access are crucial for managing this global health issue.

Keywords:
hepatitis C virusrisk factorssustained virological responseuniversal screening

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Related Experiment Videos

Last Updated: Mar 28, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Chronic hepatitis C virus (HCV) infection impacts 123 million globally.
  • HCV is a primary cause of liver cirrhosis and hepatocellular carcinoma.
  • A significant portion of those infected (75%) belong to the 1945-1965 birth cohort.

Purpose of the Study:

  • To highlight the limitations of current HCV screening recommendations.
  • To advocate for universal HCV screening.
  • To address the barriers in accessing treatment for identified HCV cases.

Main Methods:

  • Analysis of global HCV infection statistics.
  • Review of current screening guidelines and their application.
  • Assessment of treatment accessibility challenges.

Main Results:

  • Current screening recommendations targeting the 1945-1965 birth cohort are not fully implemented.
  • Many individuals who could benefit from treatment are missed due to cohort-specific screening.
  • Treatment access remains a significant obstacle for diagnosed HCV patients worldwide.

Conclusions:

  • Universal screening for HCV is optimal for comprehensive disease control.
  • Expanding screening beyond the 1945-1965 birth cohort is necessary.
  • Addressing treatment restrictions is critical to effectively manage chronic HCV infection.